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Hodgkin's lymphoma (HL) is a malignant disease of the lymphatic system. In children, the 5 year event-free 
survival rate is approximately 90%. However, the currently used therapy is associated with severe late side effects. 
Reduction of treatment intensity might reduce the risk for late toxicities but might also increase the risk for 
relapses. Therefore, it is important to identify new targets for improvement of the current therapy and development 
of new treatment strategies. 
Methods 
We established cDNA libraries from chemoresistant HL cell lines and developed a functional screening approach 
for the identification of genes which are potentially involved in the resistance against cytostatic drugs. For this end, 
we transfected the libraries into cells, treated them with cisplatin, re-isolated and sequenced the vectors from 
surviving cells. 
Results 
One of the isolated vectors contained the cDNA of a protein kinase form chromosome 6. Expression analysis 
showed that this kinase is only expressed in HL cell lines and other cancer cell lines (e.g. from Ewing sarcoma, 
neuroblastoma and leukemia) but not in normal blood cells or in normal tissues, except testis. Knock-down 
experiments and the incubation with an inhibitor of the kinase confirmed that this new factor modulates the 
chemosensitivity of HL cells. We used DNA-Microarray analyses and identified genes which were regulated by the 
kinase. Furthermore we isolated new interaction partners of the kinase and analyzed whether the kinase can be used 
as new target for immunotherapy. 
Conclusion 
Our data indicate that the identified kinase is associated with the resistance of the cells against cytostatic drugs and 
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